ReviewDrugs2000
Pancreatic cancer: a review of emerging therapies.
Review in Drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 94 citations in OpenAlex.
- circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway.Biology direct · 2023Article
- Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase.Cancer & metabolism · 2020Article
- Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.BMC cancer · 2018Article
- Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells.Oncology letters · 2016Article
- The influence of SnoN gene silencing by siRNA on the cell proliferation and apoptosis of human pancreatic cancer cells.Diagnostic pathology · 2015Article
- Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome.PloS one · 2014Article
- Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.Journal of biomedicine & biotechnology · 2011Review
- Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.PloS one · 2010Article
- Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice.World journal of gastroenterology · 2009Article
- Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells.International journal of cancer · 2009Article
- Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.Pharmaceutical research · 2006Article
- mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.Pharmacology & therapeutics · 2006Review
- Article
- Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein.Oncogene · 2004Article
- Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models.Cancer gene therapy · 2004Article
- Article
- Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.Journal of molecular medicine (Berlin, Germany) · 2003Article
- A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractArticle
- Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of adenocarcinoma of the pancreas has risen steadily over the past 4 decades. Since pancreatic cancer is diagnosed at an advanced stage, and because of the lack of effective therapies, the prognosis of such patients is extremely poor. Despite advances in our understanding of the molecular biology of pancreatic cancer, the systemic treatment of this disease remains unsatisfactory. Conventional chemotherapy has not produced dramatic improvements in response rates or patient survival. New treatment strategies are clearly needed. This paper reviews emerging therapies for pancreatic carcinoma. A more profound understanding of the molecular biology of cell growth and proliferation, as well as of neoplastic cell transformation, has led to advances in several areas, including the use of somatostatin analogues and antiandrogens as adjuvant therapy; inhibition of tumour growth and metastasis by inhibitors of matrix metalloproteinases and angiogenesis, and by small molecules such as retinoids, which interfere with progression through the cell cycle; immunotherapy with monoclonal antibodies; disruption of intracellular signal transduction with farnesyltransferase inhibitors; and finally gene therapy with specifically designed vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.